<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01408381</url>
  </required_header>
  <id_info>
    <org_study_id>CMMo/ICC/2009</org_study_id>
    <secondary_id>2009-013636-20</secondary_id>
    <nct_id>NCT01408381</nct_id>
  </id_info>
  <brief_title>Intra-arterial Infusion of Autologous Bone Marrow Mononuclear Cells in Non-diabetic Patients With Critical Limb Ischemia (CLI).</brief_title>
  <official_title>Multicenter Phase II, Randomized Open Clinical Trial on the Therapeutic Use of Intra-arterial Infusion of Autologous Bone Marrow Mononuclear Cells in Non-diabetic Patients With Critical Chronic Ischemia of Lower Limbs (CLI).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iniciativa Andaluza en Terapias Avanzadas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II Clinical Trial, a prospective, multicenter, open, randomized, parallel-group
      controlled with three levels of dose.

      The hypothesis of the test we propose is that the mononuclear cells of bone marrow provide
      progenitor cells with regenerative capacity and besides secrete several angiogenic factors,
      and their implantation into ischemic tissues with both elements should contribute to
      angiogenesis and tissue regeneration with recovery of the circulation in the affected limb.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study population will consist of a total of 44 non-diabetic patients with chronic
      critical ischemia in at least one of their lower limbs (CLI) and without possibility of
      revascularization. In the experimental group will be included a total of 33 patients divided
      into three levels of dose, 11 patients in each level (increasing dose of mononuclear cells
      from autologous bone marrow) and other 11 patients in control group.

        -  11 patients in group 1 will not receive cell therapy, and they will only receive
           conventional treatment, acting as a control group.

        -  11 patients in group 2 will receive 1x108 autologous bone marrow mononuclear cells.

        -  11 patients in group 3 will receive 5x108 autologous bone marrow mononuclear cells.

        -  11 patients in group 4 will receive 1x109 autologous bone marrow mononuclear cells.

      The cell therapy drug will be administered intra-arterially in all cases. Patients will be
      evaluated by clinical, radiological and angiological methods (ankle / brachial pressure
      index, transcutaneous oxygen pressure, perimeter calf muscle, presence of ulcers, oximetry
      and digital arteriography).

      Patients will receive concomitant drug treatment established by the good clinical practice,
      so undoubtedly it could be possible that some improvement occurs due to drug treatment.

      It is estimated that the inclusion period is approximately 42 months, and the follow-up of
      each patient of six months. Therefore the total duration of the study will be about forty
      eight months from the entry of the first patient to the end of the follow-up period of the
      last patient included.

      The primary variable is the improvement in the vascularisation of the treated limb determined
      by clinical, angiographic and angiologist parameters.

      Study objectives :

      • Main objective: To evaluate the safety and feasibility of the autotransplantation of
      autologous bone marrow mononuclear cells administered intra-arterially in non-diabetic
      patients with critical chronic ischemia of the lower limbs without possibility of either
      revascularization or other therapeutic alternatives.

      Secondary objectives:

        1. To compare the effect of three increasing dose of mononuclear cells from autologous bone
           marrow in the recovery of clinical, angiographic angiologist parameters in non-diabetic
           patients with critical chronic ischemia of lower limbs to a control group that will have
           been applied to a conventional treatment.

        2. To analyze complications from regenerative therapy itself, from the route of
           administration and / or study procedures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ankle-brachial index</measure>
    <time_frame>1 month, 3 months, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcutaneous oxygen pressure (TcO2)</measure>
    <time_frame>1 month, 3 months, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Greater ulcer size</measure>
    <time_frame>1 month, 3 months, 6 months</time_frame>
    <description>Ulcer diameter will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of Rutherford-Becker</measure>
    <time_frame>1 month, 3 months, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perimeter calf muscle</measure>
    <time_frame>1 month, 3 months, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of faster opacity in infrapopliteal vessels at 6 months compared with the basal situation of the patient.</measure>
    <time_frame>1 month, 3 month, 6 month</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Critical Limb Ischemia (CLI)</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No cell therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells: 1 x 108</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells: 5 x 108</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells: 1 x 109</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells</intervention_name>
    <description>Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x108, 5x108 and 1x109 low, intermediate and high dose in the arms respectively.</description>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_label>Intermediate dose</arm_group_label>
    <arm_group_label>High dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of both sexes aged ≥ 18 and ≤ 89 years.

          -  Non-diabetic.

          -  Infrapopliteal atherosclerotic vascular disease with severe to severe claudication or
             Rutherford-Becker grade I-3, II, III, in at least one lower limb. The chronic critical
             ischemia of the lower limb is defined as persistent / recurring pain requiring
             analgesia and / or non-healing ulcers present&gt; 4 weeks, with no evidence of
             improvement with conventional therapies and / or walking test (stress test) between
             1-6 minutes two exercise tests separated by at least 2 weeks and / or ankle-brachial
             index at rest &lt;0.8.

          -  Inability to endovascular or surgical revascularization as recommended by the
             TransAtlantic Inter-Society Consensus (TASC).

          -  Failure of the revascularization surgical performed at least 30 days before, either
             persistently or entry in critical ischemia phase.

          -  Life expectancy&gt; 2 years.

          -  Not expected major amputation in the limb to treat in the next 6 months after
             inclusion.

          -  Normal laboratory parameters, defined by:

               1. Leukocytes ≥ 3000

               2. Neutrophils ≥ 1500

               3. Platelets ≥ 100,000

               4. Aspartate aminotransferase AST) / Alanine aminotransferase (ALT) ≤ 2.5 standard
                  range institution.

               5. Creatinine ≤ 2.5 mg / dl

          -  Patients should give their written informed consent to participate in the study.

          -  Women of childbearing potential must have negative results on a pregnancy test
             following standard procedures for each hospital performed at the time of inclusion in
             the study and agree to use a medically approved method of contraception through the
             duration of the study.

        Exclusion Criteria:

          -  History of malignancy or hematologic disease (myeloproliferative disease,
             myelodysplastic syndrome or leukemia)

          -  Patients with uncontrolled hypertension (defined as blood pressure&gt; 180/110 on more
             than one occasion).

          -  Severe heart failure (New York Heart Association IV).

          -  Patients with malignant ventricular arrhythmias or unstable angina.

          -  Diagnosis of deep vein thrombosis in the previous 3 months.

          -  Active infection or gangrene wet day infusion of mononuclear bone marrow cells.

          -  Corporal mass index (BMI)&gt; 40 kg/m2.

          -  Patients with a diagnosis of alcoholism at the time of inclusion.

          -  Proliferative retinopathy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inmaculada Herrera, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Reina Sofía, Córdoba.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Chacon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Reina Sofia, Córdoba</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diego Martinez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Morales Meseguer, Murcia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose P Linares, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital San Cecilio, Granada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vicente Garcia, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Virgen de las Nieves, Granada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andres Garcia, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Nuestra Señora de Valme, Sevilla</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel Piñero, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Puerta del Mar, Cádiz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando Calleja, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Carlos Haya, Málaga</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Reina Sofía</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Puerta del Mar</name>
      <address>
        <city>Cádiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hopistal Carlos Haya</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Nuestra Señora de Valme</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.juntadeandalucia.es/terapiasavanzadas/</url>
    <description>Andalusian Initiative for Advanced Therapies</description>
  </link>
  <link>
    <url>http://www.cabimer.es</url>
    <description>Andalusian Molecular Biology and Regenerative Medicine Centre</description>
  </link>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2011</study_first_submitted>
  <study_first_submitted_qc>August 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2011</study_first_posted>
  <last_update_submitted>March 15, 2016</last_update_submitted>
  <last_update_submitted_qc>March 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Critical Limb Ischemia (CLI)</keyword>
  <keyword>Cell Therapy</keyword>
  <keyword>Bone marrow mononuclear cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

